65900 Federal Register / Vol. 70, No.
210 / Tuesday, November 1, 2005 / Notices
Region 5, Ground Water and Drinking
Water Branch (WG–15J), 77 West
Jackson Boulevard, Chicago, Illinois
60604, between the hours of 9 a.m. and
4:30 p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT:
Margarita Chacon, EPA Region 5,
Ground Water and Drinking Water
Branch, at the address given above, by
telephone at (312) 886–0225, or at
chacon.margarita@epa.gov.
Authority: (Section 1413 of the Safe
Drinking Water Act, as amended, 42 U.S.C.
3006–2 (1996), and 40 CFR part 142 of the
National Primary Drinking Water
Regulations).
Dated: October 24, 2005.
Norman Niedergang,
Acting Regional Administrator, Region 5.
[FR Doc. 05–21748 Filed 10–31–05; 8:45 am]
BILLING CODE 6560–50–P
EXPORT-IMPORT BANK OF THE
UNITED STATES
Sunshine Act Meeting
ACTION: Notice of a Partially Open
Meeting of the Board of Directors of the
Export-Import Bank of the United
States.
TIME AND PLACE: Friday, November 4,
2005 at 11:30 a.m. The Meeting will be
held at Ex-Im Bank in Room 1143, 811
Vermont Avenue, NW., Washington, DC
20571.
OPEN AGENDA ITEM: Ex-Im Bank Sub-
Saharan Africa Advisory Committee for
2006.
PUBLIC PARTICIPATION: The meeting will
be open to public participation for Item
No. 1 only.
FOR FURTHER INFORMATION CONTACT: For
further information, contact: Office of
the Secretary, 811 Vermont Avenue,
NW., Washington, DC 20571 (Tele. No.
202–565–3957).
Howard A. Schweitzer,
General Counsel (Acting).
[FR Doc. 05–21860 Filed 10–28–05; 12:58
pm]
BILLING CODE 6690–01–M
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisition of Shares of Bank or Bank
Holding Companies
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire a bank or bank
VerDate Aug<31>2005 15:39 Oct 31, 2005 Jkt 208001
holding company. The factors that are
considered in acting on the notices are
set forth in paragraph 7 of the Act (12
U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the office of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than
November 16, 2005.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261–4528:
1. Charles F. Sposato Flint Trust and
trustee Mark Wayne Saunters, Elkton,
Maryland; to control voting shares of
Cecil Bancorp, Inc., Elkton, Maryland,
and thereby indirectly acquire voting
shares of Cecil Federal Bank, Elkton,
Maryland.
Board of Governors of the Federal Reserve
System, October 27, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E5–6024 Filed 10–31–05; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 E:\FR\FM\01NON1.SGM
obtained from the National Information
Center Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than November 16, 2005.
A. Federal Reserve Bank of Atlanta
(Andre Anderson, Vice President) 1000
Peachtree Street, NE., Atlanta, Georgia
30303:
1. Cornerstone Bancshares, Inc., and
EFI Acquisition, Inc., both of
Chattanooga, Tennessee, to acquire
voting shares of Eagle Financial, LLC
and Eagle Funding, LLC, both of
Chattanooga, Tennessee, and thereby
engage in providing factoring services to
small business and services as a loan
broker serving as a facilitator to small
businesses, pursuant to section
225.28(b)(1) of Regulation Y.
Board of Governors of the Federal Reserve
System, October 27, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E5–6025 Filed 10–31–05; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
AGENCY: Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science.
ACTION: Notice.
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (DHHS) is hereby giving notice
that the Presidential Advisory Council
on HIV/AIDS (PACHA) will hold a
meeting. This meeting is open to the
public. A description of the Council’s
functions is included also with this
notice.
Date and Time: November 14, 2005,
8:30 a.m. to 5 p.m.
ADDRESSES: Department of Health and
Human Services, Hubert H. Humphrey
Building, Room 800, 200 Independence
Ave., SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Joseph Grogan, Esq., Executive Director,
Presidential Advisory Council on HIV/
AIDS, Department of Health and Human
Services, Hubert H. Humphrey Building,
200 Independence Avenue, SW., Room
736E, Washington, DC 20201; or visit
the Council’s Web site at http://
www.pacha.gov.
01NON1
 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices
SUPPLEMENTARY INFORMATION: PACHA
was established by Executive Order
12963, dated June 14, 1995, as amended
by Executive Order 13009, dated June
14, 1996. PACHA was established to
provide advice, information, and
recommendations to the President
regarding programs and policies
intended to (a) promote effective
prevention of HIV disease, (b) advance
research on HIV and AIDS, and (c)
promote quality services to persons
living with HIV disease and AIDS.
PACHA was established to serve solely
as an advisory body to the President and
the Secretary of Health and Human
Services. PACHA is composed of not
more than 21 members. PACHA
membership is determined by the
Secretary from individuals who are
considered authorities with particular
expertise in, or knowledge of, matters
concerning HIV/AIDS.
The agenda for this meeting includes
the following topics: HIV/AIDS
prevention, care and treatment, and
global HIV/AIDS issues. Time will be
allotted during the meeting for public
comment.
Public attendance is limited to space
available and pre-registration is required
for both attendance and public
comment. Any individual who wishes
to attend and/or comment must register
on-line at http://www.pacha.gov.
Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should indicate when
registering on-line.
Members of the public will have the
opportunity to provide comments at the
meeting. Public comment will be
limited to three (3) minutes per speaker
and to time available. Written
testimony, not exceed five (5) pages,
will be accepted by mail or facsimile at
202/205–4986.
Written testimony will not be
accepted after 5 p.m., Wednesday,
November 9, 2005.
Dated: October 26, 2005.
Joseph Grogan,
Executive Director, Presidential Advisory
Council on HIV/AIDS.
[FR Doc. 05–21714 Filed 10–31–05; 8:45 am]
BILLING CODE 4150–43–P
VerDate Aug<31>2005 15:39 Oct 31, 2005 Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 30, 1980, as amended
most recently at 69 FR 77756, dated
December 28, 2004) is amended to
reorganize the National Center for HIV,
STD, & TB Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the following
titles and functional statements:
Division of AIDS, STD & TB Laboratory
Research (CK7), Office of the Director
(CK71), HIV, Immunology and
Diagnostics Branch (CK72), HIV
Immunology and Diagnostics Branch
(CK73), Sexually Transmitted Infectious
Diseases Branch (CK74), Tuberculosis/
Mycobacteriology Branch (CK75).
Following the Training and Health
Communication Branch (CK37),
Division of STD Prevention (CK3), insert
the following:
Laboratory Reference and Research
Branch, (CK38). (1) Performs research
on the pathogenesis, genetics, and
immunology of syphilis and other
treponematoses, gonococcal and
chlamydial infections, chancroid,
genital herpes, donovanosis, bacterial
vaginosis and trichomoniasis; (2)
conducts and participates in clinical,
field, and laboratory research to
develop, evaluate, and improve
laboratory methods used in the
diagnosis and epidemiology of these
sexually transmitted infections (STIs);
(3) provides consultation and reference/
diagnostic services for these STIs; (4)
conducts laboratory-based surveillance
for and research on the genetics of
antimicrobial resistance in Neisseria
gonorrhoeae; (5) serves as the WHO
International Collaborating Center for
Reference and Research in Syphilis
Serology; and (6) provides consultation
and laboratory support for international
activities.
Following the International Research
and Programs Branch (CK47), Division
of Tuberculosis Elimination (CK4),
insert the following:
Mycobacteriology Branch (HCK48). (1)
Provides laboratory support for
PO 00000 Frm 00025 Fmt 4703 Sfmt 4703
65901
epidemic investigations, surveillance
activities, and special studies of
tuberculosis and other mycobacteria-
caused diseases; (2) administers
contracts to provide Mycobacterium
tuberculosis genotyping, maintains a
national database of genotypes, and
conducts operational research to
implement genotyping; (3) develops and
evaluates new methods to subtype
mycobacteria for epidemiologic studies;
(4) serves as primary CDC focus for
diagnostic mycobacteriology laboratory
services and for laboratory aspects of
nontuberculosis Mycobacterium species
and of Hansen disease (leprosy); (5)
administers grants and cooperative
agreements with states and others to
upgrade laboratory activities and
provide special services; (6) provides
reference diagnostic services,
consultation, technical assistance, and
training to State, Federal, and municipal
public health laboratories; (7) provides
laboratory support, reference services,
assessment, consultation, and training
for CDC’s international tuberculosis
activities; (8) develops, evaluates, or
improves conventional and molecular
methods for the detection, classification,
identification, characterization, and
susceptibility testing of mycobacteria
and mycobacteria-caused diseases; (9)
conducts studies to define the role of
bacterial virulence factors, host factors,
and pathogenic and immunologic
mechanisms in disease processes and
protective immunity and develops,
evaluates, and improves immunologic
methods for the diagnosis and
prevention of mycobacteria-caused
diseases; (10) develops tissue culture
and animal models of mycobacteria-
caused diseases and conducts studies on
chemotherapy, immunotherapy,
pathogenesis, pathology, and vaccines
for mycobacteria-caused diseases; (11)
conducts studies on the isolation,
taxonomy, and ecology of mycobacteria
and develops tests to identify new
species; (12) conducts and supports
studies to characterize newly emerging
pathogenic species of Mycobacterium
and associated diseases.
Following the HIV Incidence and
Case Surveillance Branch (CK56),
Division of HIV, AIDS Prevention—
Surveillance and Epidemiology (CK5),
insert the following:
HIV and Retrovirology Laboratory
Branch (HCK57). (1) Conducts studies of
human immunodeficiency viruses
(HIVs) and other human and zoonotic
retroviruses, including the diseases they
cause, their modes of transmission, and
the means for their control through
virus detection, isolation, and
characterization by virologic, molecular,
and cellular biologic methods; (2)
E:\FR\FM\01NON1.SGM 01NON1